Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Latanoprost · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SAR366234 (Dose 1) | EXPERIMENTAL | A low dose of SAR366234 will be administered 2 drops per eye per day for 28 days |
| SAR366234 (Dose 2) | EXPERIMENTAL | A medium dose of SAR366234 will be administered 1 drop per eye per day for 28 days |
| SAR366234 (Dose 3) | EXPERIMENTAL | A medium dose of SAR366234 will be administered 2 drops per eye per day for 28 days |
| SAR366234 (Dose 4) | EXPERIMENTAL | A high dose of SAR366234 will be administered 1 drop per eye per day for 28 days |
| SAR366234 (Dose 5) | EXPERIMENTAL | A high dose of SAR366234 will be administered 2 drops per eye per day for 28 days |
| Latanoprost | ACTIVE_COMPARATOR | A dose of Latanoprost will be administered 1 drop per eye per day for 28 days |
| Name | Type | Description |
|---|---|---|
| Latanoprost | DRUG | - |
| SAR366234 | DRUG | - |
Inclusion criteria: * Male or female patients ≥18 years of age. * Patients diagnosed with OAG (including pseudoexfoliation and pigment dispersion syndromes and patients with a history of narrow angle closure with a patent peripheral iridotomy) or OHT. * Documented intraocular pressure (IOP) fulfill...
Latanoprost is used for open angle glaucoma and ocular hypertension. It is an ophthalmology drug being developed by Sanofi as a small molecule. It is currently in Phase 1 clinical development, meaning it is investigational and not yet approved.
Sanofi (ticker: SNY) is developing Latanoprost. The drug is a small molecule in the ophthalmology therapeutic area, intended for open angle glaucoma and ocular hypertension. It is currently in Phase 1 clinical development.
Latanoprost is in Phase 1 clinical development. It is an investigational drug for open angle glaucoma and ocular hypertension. It has completed one Phase 1 trial, and it is not yet approved for any use.
Latanoprost has one completed clinical trial, NCT02531152, a 28-day repeated topical study evaluating safety and activity of 5 escalating dose levels of SAR366234 and one dose of Latanoprost in patients with open angle glaucoma or ocular hypertension. The trial enrolled 54 participants in the United States.
No, Latanoprost is not the same as SAR366234. In the clinical trial NCT02531152, both drugs were studied separately: SAR366234 was given at 5 escalating dose levels, while Latanoprost was given at one dose. They are distinct investigational drugs.